Developer docs
API playgroundTry for free, no card

Search company profiles

HydRegen

Full company profile

uuid0002yzu

Namestring
HydRegen
Legal namestring
HydRegen Limited
Company typeenum
Private
Founded yearint
2021
Descriptiontext

HydRegen Limited is a UK industrial biotechnology company founded in March 2021 as a spinout from the Department of Chemistry, University of Oxford, with headquarters in Oxford and additional incubation space at the Wilton Centre in Tees Valley. The company's core technology is a proprietary biocatalytic hydrogenation platform built on hydrogenase enzymes that use hydrogen gas (H2) as a clean energy source, enabling nitro-to-amine reductions and other hydrogenation reactions to replace precious metal catalysts (palladium, platinum, nickel) under mild conditions (1 bar H2, 25-60°C, ambient temperatures) without metal complexes, co-catalysts, or cofactors.

HydRegen operates two productised offerings: Bio2Amine, a heterogeneous biocatalyst for selective aromatic nitro-to-amine conversions that has demonstrated >30 reactions with full conversion and high isolated yield (including APIs such as paracetamol, mesalazine, sildenafil, linezolid, and intermediates like aniline and naphthylamine), with >4 million enzyme turnovers and operation for over a week in continuous flow; and H2BioCat, a hydrogenase-based platform providing 100% atom-efficient NADH or flavin cofactor recycling to support a wider class of cofactor-dependent enzymes. The technology is positioned as 'slot-in', designed to operate within existing chemical manufacturing infrastructure (batch or continuous flow) without capex retooling, and has been validated to deliver 40-50% cost savings and 3x CO2e reductions versus metal-catalyzed processes.

Commercially, the company monetises through a land-and-expand motion: evaluation sample sales (with >50% conversion to orders), joint development agreements (with Almac Sciences, AM Technology, JRSI, and a confidential large chemicals company), and ultimately technology licensing and royalty arrangements for commercial manufacturing. Its primary customers are pharmaceutical manufacturers (APIs and intermediates such as paracetamol) and fine and specialty chemical producers, with a secondary expansion vector into bulk commodities. The company has raised approximately £3.4M cumulatively across three disclosed rounds (Innovate UK/Oxford Seed Challenge Fund 2021, UKI2S 2022, Clean Growth Fund 2023), was awarded a 2024 Golden Ticket for planetary health innovation, and published its underpinning Bio2Amine science in Nature Communications in August 2024.

Short descriptiontext

HydRegen is an Oxford University spinout developing bio-based hydrogenation catalysts that replace precious metal catalysts in pharmaceutical and fine chemical manufacturing, licensing its Bio2Amine and H2BioCat enzyme platforms to industrial customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biocatalytic hydrogenation, sustainable chemical manufacturing, nitro-to-amine conversion, biocatalysis technology, green chemistry catalysts
Industry2 codes
PRIMARYIMAEAIAD
Chemical Synthesis Catalysts (Hydrogenation/Oxidation/Acid-Base)
SECONDARYEUABAJAC
Hydrogen & Derivative Fuels for Industry (H₂, Ammonia, Methanol)
Energy, Utilities & Environment/Carbon & Climate Solutions (Carbon Markets, Offsets, CCS/CCUS)/Industrial Decarbonization Solutions (Process Heat, Electrification, Fuel Switching)
NAICS code2 codes
  • Chemical Manufacturing325
  • Basic Chemical Manufacturing3251
SIC code2 codes
  • Industrial Organic Chemicals2860
  • Miscellaneous Chemical Products2890
Product category
Industrial Biotechnology
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing
TypeLicensing Royalties
Description

HydRegen licenses its Bio2Amine and H2BioCat technologies to pharmaceutical and chemical companies for commercial manufacturing. Licensing agreements provide recurring revenue from royalties and milestone payments.

hydregenoxford.com
2Joint Development Projects
TypeProfessional Services
Description

Collaborative development agreements with major chemicals and pharmaceutical companies to develop and optimize specific processes using HydRegen's technology. Customers include Almac Sciences and AM Technology partnerships.

hydregenoxford.com
3Evaluation Products
TypeOne Time License
Description

Sale of Bio2Amine evaluation samples allowing customers to assess the technology for their specific applications. Customer progression to orders exceeds 50% from evaluation samples.

hydregenoxford.com
4Option to License Agreements
TypeLicensing Royalties
Description

Companies can option to license technology before full commercial licensing, providing revenue opportunities and customer lock-in.

hydregenoxford.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Evaluation samples for technology assessment
ModelOtherBilling cadencePay-as-you-go
Notes

Evaluation products allow customers to rapidly assess nitro-to-amine reductions in their own facilities. Customer feedback is leveraged through data exchange discounts to enhance products.

hydregenoxford.com
2Joint development projects for process optimization
ModelOtherBilling cadenceMulti-year contract
Notes

Custom development agreements tailored to customer requirements with deliverables on joint development work. Includes access to HydRegen expertise and know-how for process optimization.

hydregenoxford.com
3Technology licensing for commercial manufacturing
ModelLicensing/ royaltiesBilling cadenceMulti-year contract
Notes

Licensing agreements for commercial deployment of Bio2Amine and H2BioCat technologies. Option to license agreements also available.

hydregenoxford.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Bio2Amine
Description

A heterogeneous biocatalyst for aromatic nitro-to-amine conversions, applicable in batch or continuous flow, used for producing specialty/bulk chemicals and active pharmaceutical ingredients including paracetamol, mesalazine, aniline, and others.

hydregenoxford.com
+1 more record
Core offering1 text field

HydRegen develops and commercializes proprietary biocatalytic hydrogenation technology that replaces toxic, finite precious metal catalysts in chemical manufacturing with bio-based enzyme alternatives. The company's two core offerings are Bio2Amine, a heterogeneous biocatalyst for selective aromatic nitro-to-amine conversions, and H2BioCat, a hydrogenase-based technology platform providing 100% atom-efficient cofactor recycling for hydrogen-driven biocatalysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 40-50% cost savings compared to traditional metal-catalyzed processes
+6 more records
Product overview1 text field

HydRegen offers a portfolio of industrial biotechnology platforms that deliver sustainable, safe and cost-efficient chemical processes. The company has two core products: Bio2Amine, a heterogeneous biocatalyst for selective nitro-to-amine conversions (targeting aromatic amines used in pharmaceuticals, specialty and bulk chemicals), and H2BioCat, a hydrogenase-based technology platform for NADH/flavin cofactor recycling that powers biocatalytic hydrogenation. These 'slot-in' technologies are designed as replacements to precious metal catalysts in existing chemical manufacturing infrastructure, enabling 3x CO2e savings and 40% cost savings for customers without requiring infrastructure changes.

Product and service5 records
1Bio2Amine
CategoryBiocatalyst
Description

Bio2Amine is a heterogeneous biocatalyst that enables selective aromatic nitro-to-amine conversions. The technology shows excellent scope, selectivity and productivity for converting aromatic nitro compounds to amines, handling 16 documented reactions including specialty/bulk chemicals (4-Chloroaniline, 4-Fluoroaniline, Aniline, Naphthylamine, meta/ortho/para-phenylenediamine) and active pharmaceutical ingredients (Paracetamol, Mesalazine, Sildenafil, Erlotinib, Linezolid). Achieves >30 aromatic nitro-to-amine reactions with full conversion and high isolated yield, no dehalogenation, no C=X reductions, no deactivation by S-containing functional groups. The carbon-supported catalyst achieves full conversion over 5 reuse cycles, operates under 1 bar H2 gas with no requirement for metal complexes, co-catalysts or cofactors. Can be operated in batch or continuous flow for pharmaceutical and chemical manufacturers.

2H2BioCat
CategoryBiotransformation platform
Description

H2BioCat is a hydrogenase-based technology platform that supports NADH- or flavin-dependent enzymes, providing a 100% atom efficient cofactor recycling system. It enables intensification of process conditions by switching the power source for biocatalysis from glucose to hydrogen gas. The platform operates with ease of production and handling for metallo-enzyme production, enabling clean and efficient hydrogen-powered biocatalytic hydrogenation for pharmaceutical and chemical manufacturers.

3Bio2Amine Evaluation Samples
CategoryEvaluation product
Description

Bio2Amine Evaluation Samples are heterogeneous biocatalyst evaluation products that allow customers to rapidly assess the Bio2Amine technology for nitro-to-amine reductions in their own facilities. Designed to mimic metal/carbon catalyst handling for ease of implementation. Customer feedback is leveraged through data exchange discounts to enhance products. Over 50% of evaluation customers progress to orders.

4Joint Development Projects
CategoryJoint development services
Description

Joint Development Projects are collaborative development agreements where HydRegen works with pharmaceutical and chemical companies to develop and optimize specific processes using its Bio2Amine and H2BioCat technologies. Customers include Almac Sciences, AM Technology, and James Robinson Speciality Ingredients (JRSI). Deliverables include process optimization, scale-up demonstrations, and technology transfer. Custom development agreements tailored to customer requirements, with access to HydRegen expertise and know-how.

5Technology Licensing
CategoryTechnology licensing
Description

Technology Licensing agreements provide pharmaceutical and chemical companies with the rights to deploy HydRegen's Bio2Amine and H2BioCat technologies for commercial manufacturing. Licensing agreements provide recurring revenue from royalties and milestone payments. Option to license agreements are also available before full commercial licensing. The licensing model enables customers to integrate HydRegen's biocatalytic hydrogenation technology into their existing chemical manufacturing infrastructure for commercial-scale production.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-11
Description

Strategic collaboration announced June 2025 to implement sustainable and efficient manufacturing processes through application of HydRegen's Bio2Amine biocatalyst technology.

Strategic tierFoundationalTypeStrategic or Co-development PartnerAnnounced on2024-08-27
Description

Source of foundational academic research. 10+ years of research from Department of Chemistry developed the hydrogenase technology. Collaborative research effort published in Nature Communications.

Strategic tierSupportTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-05-10
Description

Golden Ticket programme winner providing 12 months of venture development support. Partnership with CPI for scale-up and innovation support including grant landscape review, technical consultancy, and test facilities access.

Strategic tierSupportTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-05-10
Description

Part of High Value Manufacturing Catapult providing tailored grant landscape review, bid development, technical consultancy, innovation support, one-to-one technology advisory sessions, and use of test facilities at Wilton Centre.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2023-08-29
Description

BBSRC, EPSRC and Innovate UK funded collaboration focused on intensification and scaling enzyme production for quinuclidinol manufacturing. Dr Simone Morra's team brings expertise in novel hydrogen cycling enzymes for metallo-enzyme production.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Innovate UK funded collaborative project (>£0.9m) for scaling Bio2Amine for manufacturing of paracetamol intermediate and another active pharmaceutical ingredient. Combines continuous hydrogenation infrastructure with Bio2Amine technology.

Strategic tierSupportTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Sister company to Clean Growth Fund providing commercial strategy support. Analyzed aromatic amine market to identify key chemical products where HydRegen can offer competitive advantages.

Strategic tierSupportTypeOthersAnnounced on2023-01-01
Description

Leadership development partner providing ScaleUp Institute endorsed Horizon Method programme. Helped transform leadership from technical perfectionism to commercial momentum and pace.

9Almac Sciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-01
Description

Joint development partnership with pharmaceutical and fine chemical company for large-scale manufacture using multi-enzyme system. Successfully completed tech transfer and achieved >99.9% conversion in kilo-lab hydrogenation facility demonstrating first scale-up of joint manufacturing route.

hydregenoxford.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

University of Oxford spinout developing enzyme-based processes for chemical manufacturing, including oxidation and hydroxylation reactions. Direct peer in the UK biocatalysis-for-fine-chemicals space, sharing Oxford roots, target customers (pharma/chemical manufacturers), and an enzyme licensing/collaboration model.

TypeEmerging player
Description

Scotland-based industrial biotechnology and synthetic biology company providing contract biocatalysis and fermentation services to pharma, chemicals, and consumer products companies. Emerging player in UK biocatalysis with overlapping customers and a similar use of engineering biology for sustainable chemical manufacturing, though focused on service/contract rather than licensing.

TypeDirect peer
Description

Leading US-listed enzyme engineering company focused on biocatalysis for pharmaceutical and chemical manufacturing. Directly comparable to HydRegen as both develop engineered enzymes/biocatalysts as drop-in or process-enabling catalysts for fine chemical and API production, with similar licensing and supply business models.

TypeBroad incumbent
Description

Global specialty chemicals and sustainable technologies company with a major precious-metal catalysts business serving pharmaceutical and chemical manufacturers. Broad incumbent that HydRegen's biocatalytic hydrogenation directly competes with, especially in nitro-to-amine and other hydrogenation reactions where palladium and platinum catalysts are standard.

TypeBroad incumbent
Description

Major German specialty chemicals company with a sizable biocatalysis and enzyme production operation (formerly Evonik Creavis) addressing pharma, cosmetics, and fine chemicals. Broad incumbent that combines established commercial reach with internal biocatalysis R&D, creating a credible competitor and potential partner/customer for HydRegen's hydrogenation technology.

TypeBroad incumbent
Description

World-leading industrial enzyme company (recently merged with Chr. Hansen to form Novonesis) serving detergent, food, agriculture, and increasingly pharma/biocatalysis markets. Broad incumbent with deep enzyme engineering capability, established global sales channels, and capital scale that dwarf HydRegen, making it a potential competitor and partner in pharmaceutical biocatalysis.

TypeDirect peer
Description

US-based protein design company that uses computational enzyme design to develop novel biocatalysts for chemical manufacturing. Direct peer in the designer-enzyme-for-fine-chemicals space, sharing HydRegen's model of engineering enzymes to displace traditional chemical catalysts and license the resulting processes.

TypeDirect peer
Description

UK-based specialist in continuous flow hydrogenation and reactor technology for pharmaceutical and fine chemical manufacturing. Listed as an active HydRegen partner on the Innovate UK-funded paracetamol scale-up project, and a direct peer/adjacent technology provider in continuous flow hydrogenation that competes for the same slots in customer process lines.

TypeBroad incumbent
Description

World's largest chemical company with broad catalyst, biocatalysis, and process chemistry capabilities serving pharma, agro, and specialty chemical customers. Broad incumbent whose scale, in-house biocatalysis programs (e.g., with universities), and pricing power could constrain HydRegen's commercial expansion into large accounts.

10Almac Sciences
TypeOthers
Description

Pharmaceutical and fine chemicals CDMO that is both a HydRegen customer/partner (joint development, completed tech transfer of H2BioCat) and a service provider to many of HydRegen's target customers. Acts as an adjacent channel and ecosystem participant whose process development and scale-up infrastructure HydRegen leverages to reach pharma manufacturers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HydRegen

Industrial Biotechnologyhydregenoxford.com

HydRegen is an Oxford University spinout developing bio-based hydrogenation catalysts that replace precious metal catalysts in pharmaceutical and fine chemical manufacturing, licensing its Bio2Amine and H2BioCat enzyme platforms to industrial customers.

What HydRegen does

HydRegen Limited is a UK industrial biotechnology company founded in March 2021 as a spinout from the Department of Chemistry, University of Oxford, with headquarters in Oxford and additional incubation space at the Wilton Centre in Tees Valley. The company's core technology is a proprietary biocatalytic hydrogenation platform built on hydrogenase enzymes that use hydrogen gas (H2) as a clean energy source, enabling nitro-to-amine reductions and other hydrogenation reactions to replace precious metal catalysts (palladium, platinum, nickel) under mild conditions (1 bar H2, 25-60°C, ambient temperatures) without metal complexes, co-catalysts, or cofactors.

HydRegen operates two productised offerings: Bio2Amine, a heterogeneous biocatalyst for selective aromatic nitro-to-amine conversions that has demonstrated >30 reactions with full conversion and high isolated yield (including APIs such as paracetamol, mesalazine, sildenafil, linezolid, and intermediates like aniline and naphthylamine), with >4 million enzyme turnovers and operation for over a week in continuous flow; and H2BioCat, a hydrogenase-based platform providing 100% atom-efficient NADH or flavin cofactor recycling to support a wider class of cofactor-dependent enzymes. The technology is positioned as 'slot-in', designed to operate within existing chemical manufacturing infrastructure (batch or continuous flow) without capex retooling, and has been validated to deliver 40-50% cost savings and 3x CO2e reductions versus metal-catalyzed processes.

Commercially, the company monetises through a land-and-expand motion: evaluation sample sales (with >50% conversion to orders), joint development agreements (with Almac Sciences, AM Technology, JRSI, and a confidential large chemicals company), and ultimately technology licensing and royalty arrangements for commercial manufacturing. Its primary customers are pharmaceutical manufacturers (APIs and intermediates such as paracetamol) and fine and specialty chemical producers, with a secondary expansion vector into bulk commodities. The company has raised approximately £3.4M cumulatively across three disclosed rounds (Innovate UK/Oxford Seed Challenge Fund 2021, UKI2S 2022, Clean Growth Fund 2023), was awarded a 2024 Golden Ticket for planetary health innovation, and published its underpinning Bio2Amine science in Nature Communications in August 2024.

HydRegen firmographics

Firmographics
Name
HydRegen
Legal name
HydRegen Limited
Website
https://hydregenoxford.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
HydRegen is an Oxford University spinout developing bio-based hydrogenation catalysts that replace precious metal catalysts in pharmaceutical and fine chemical manufacturing, licensing its Bio2Amine and H2BioCat enzyme platforms to industrial customers.
Ownership category
akta.pro rank

HydRegen industry classification

Industry
Product category
Industrial Biotechnology
NAICS
Chemical Manufacturing (325), Basic Chemical Manufacturing (3251)
SIC
Industrial Organic Chemicals (2860), Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYIMAEAIAD
Chemical Synthesis Catalysts (Hydrogenation/Oxidation/Acid-Base)
SECONDARYEUABAJAC
Hydrogen & Derivative Fuels for Industry (H₂, Ammonia, Methanol)
Energy, Utilities & Environment/Carbon & Climate Solutions (Carbon Markets, Offsets, CCS/CCUS)/Industrial Decarbonization Solutions (Process Heat, Electrification, Fuel Switching)

Keywords

  • Biocatalytic hydrogenation
  • Sustainable chemical manufacturing
  • Nitro-to-amine conversion
  • Biocatalysis technology
  • Green chemistry catalysts

Where HydRegen is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

HydRegen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing: HydRegen licenses its Bio2Amine and H2BioCat technologies to pharmaceutical and chemical companies for commercial manufacturing. Licensing agreements provide recurring revenue from royalties and milestone payments.
  2. Joint Development Projects: Collaborative development agreements with major chemicals and pharmaceutical companies to develop and optimize specific processes using HydRegen's technology. Customers include Almac Sciences and AM Technology partnerships.
  3. Evaluation Products: Sale of Bio2Amine evaluation samples allowing customers to assess the technology for their specific applications. Customer progression to orders exceeds 50% from evaluation samples.
  4. Option to License Agreements: Companies can option to license technology before full commercial licensing, providing revenue opportunities and customer lock-in.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goEvaluation samples for technology assessment
OtherMulti-year contractJoint development projects for process optimization
Licensing/ royaltiesMulti-year contractTechnology licensing for commercial manufacturing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

HydRegen product offering

Product offering

Core offering

HydRegen develops and commercializes proprietary biocatalytic hydrogenation technology that replaces toxic, finite precious metal catalysts in chemical manufacturing with bio-based enzyme alternatives. The company's two core offerings are Bio2Amine, a heterogeneous biocatalyst for selective aromatic nitro-to-amine conversions, and H2BioCat, a hydrogenase-based technology platform providing 100% atom-efficient cofactor recycling for hydrogen-driven biocatalysis.

Product overview

HydRegen offers a portfolio of industrial biotechnology platforms that deliver sustainable, safe and cost-efficient chemical processes. The company has two core products: Bio2Amine, a heterogeneous biocatalyst for selective nitro-to-amine conversions (targeting aromatic amines used in pharmaceuticals, specialty and bulk chemicals), and H2BioCat, a hydrogenase-based technology platform for NADH/flavin cofactor recycling that powers biocatalytic hydrogenation. These 'slot-in' technologies are designed as replacements to precious metal catalysts in existing chemical manufacturing infrastructure, enabling 3x CO2e savings and 40% cost savings for customers without requiring infrastructure changes.

Differentiator

Problem solved

Functional benefit

Brands

  • Bio2Amine: A heterogeneous biocatalyst for aromatic nitro-to-amine conversions, applicable in batch or continuous flow, used for producing specialty/bulk chemicals and active pharmaceutical ingredients including paracetamol, mesalazine, aniline, and others.
  • H2BioCat

Products and services

  • Bio2Amine Bio2Amine is a heterogeneous biocatalyst that enables selective aromatic nitro-to-amine conversions. The technology shows excellent scope, selectivity and productivity for converting aromatic nitro compounds to amines, handling 16 documented reactions including specialty/bulk chemicals (4-Chloroaniline, 4-Fluoroaniline, Aniline, Naphthylamine, meta/ortho/para-phenylenediamine) and active pharmaceutical ingredients (Paracetamol, Mesalazine, Sildenafil, Erlotinib, Linezolid). Achieves >30 aromatic nitro-to-amine reactions with full conversion and high isolated yield, no dehalogenation, no C=X reductions, no deactivation by S-containing functional groups. The carbon-supported catalyst achieves full conversion over 5 reuse cycles, operates under 1 bar H2 gas with no requirement for metal complexes, co-catalysts or cofactors. Can be operated in batch or continuous flow for pharmaceutical and chemical manufacturers.
  • H2BioCat H2BioCat is a hydrogenase-based technology platform that supports NADH- or flavin-dependent enzymes, providing a 100% atom efficient cofactor recycling system. It enables intensification of process conditions by switching the power source for biocatalysis from glucose to hydrogen gas. The platform operates with ease of production and handling for metallo-enzyme production, enabling clean and efficient hydrogen-powered biocatalytic hydrogenation for pharmaceutical and chemical manufacturers.
  • Bio2Amine Evaluation Samples Bio2Amine Evaluation Samples are heterogeneous biocatalyst evaluation products that allow customers to rapidly assess the Bio2Amine technology for nitro-to-amine reductions in their own facilities. Designed to mimic metal/carbon catalyst handling for ease of implementation. Customer feedback is leveraged through data exchange discounts to enhance products. Over 50% of evaluation customers progress to orders.
  • Joint Development Projects Joint Development Projects are collaborative development agreements where HydRegen works with pharmaceutical and chemical companies to develop and optimize specific processes using its Bio2Amine and H2BioCat technologies. Customers include Almac Sciences, AM Technology, and James Robinson Speciality Ingredients (JRSI). Deliverables include process optimization, scale-up demonstrations, and technology transfer. Custom development agreements tailored to customer requirements, with access to HydRegen expertise and know-how.
  • Technology Licensing Technology Licensing agreements provide pharmaceutical and chemical companies with the rights to deploy HydRegen's Bio2Amine and H2BioCat technologies for commercial manufacturing. Licensing agreements provide recurring revenue from royalties and milestone payments. Option to license agreements are also available before full commercial licensing. The licensing model enables customers to integrate HydRegen's biocatalytic hydrogenation technology into their existing chemical manufacturing infrastructure for commercial-scale production.

Quantifiable outcome

  • 40-50% cost savings compared to traditional metal-catalyzed processes
  • +6 more outcomes

Companies that use HydRegen

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

HydRegen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

HydRegen partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, foundational, support and key.

  • James Robinson Speciality Ingredients (JRSI)coreStrategic or Co-development Partner · 11 June 2025Strategic collaboration announced June 2025 to implement sustainable and efficient manufacturing processes through application of HydRegen's Bio2Amine biocatalyst technology.
  • University of Oxford - Prof Kylie Vincent GroupfoundationalStrategic or Co-development Partner · 27 August 2024Source of foundational academic research. 10+ years of research from Department of Chemistry developed the hydrogenase technology. Collaborative research effort published in Nature Communications.
  • Pioneer GroupsupportImplementation/ SI/ Consulting Partner · 10 May 2024Golden Ticket programme winner providing 12 months of venture development support. Partnership with CPI for scale-up and innovation support including grant landscape review, technical consultancy, and test facilities access.
  • CPI (Centre for Process Innovation)supportImplementation/ SI/ Consulting Partner · 10 May 2024Part of High Value Manufacturing Catapult providing tailored grant landscape review, bid development, technical consultancy, innovation support, one-to-one technology advisory sessions, and use of test facilities at Wilton Centre.
  • University of NottinghamkeyStrategic or Co-development Partner · 29 August 2023BBSRC, EPSRC and Innovate UK funded collaboration focused on intensification and scaling enzyme production for quinuclidinol manufacturing. Dr Simone Morra's team brings expertise in novel hydrogen cycling enzymes for metallo-enzyme production.
  • AM TechnologykeyStrategic or Co-development Partner · 1 January 2023Innovate UK funded collaborative project (>£0.9m) for scaling Bio2Amine for manufacturing of paracetamol intermediate and another active pharmaceutical ingredient. Combines continuous hydrogenation infrastructure with Bio2Amine technology.
  • Carbon Limiting TechnologiessupportStrategic or Co-development Partner · 1 January 2023Sister company to Clean Growth Fund providing commercial strategy support. Analyzed aromatic amine market to identify key chemical products where HydRegen can offer competitive advantages.
  • Horizon37supportOthers · 1 January 2023Leadership development partner providing ScaleUp Institute endorsed Horizon Method programme. Helped transform leadership from technical perfectionism to commercial momentum and pace.
  • Almac SciencescoreStrategic or Co-development Partner · 1 March 2022Joint development partnership with pharmaceutical and fine chemical company for large-scale manufacture using multi-enzyme system. Successfully completed tech transfer and achieved >99.9% conversion in kilo-lab hydrogenation facility demonstrating first scale-up of joint manufacturing route.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

HydRegen competitors and assessment

Company assessment

Direct peers

  • Oxford Biotrans: University of Oxford spinout developing enzyme-based processes for chemical manufacturing, including oxidation and hydroxylation reactions. Direct peer in the UK biocatalysis-for-fine-chemicals space, sharing Oxford roots, target customers (pharma/chemical manufacturers), and an enzyme licensing/collaboration model.
  • Codexis: Leading US-listed enzyme engineering company focused on biocatalysis for pharmaceutical and chemical manufacturing. Directly comparable to HydRegen as both develop engineered enzymes/biocatalysts as drop-in or process-enabling catalysts for fine chemical and API production, with similar licensing and supply business models.
  • Arzeda: US-based protein design company that uses computational enzyme design to develop novel biocatalysts for chemical manufacturing. Direct peer in the designer-enzyme-for-fine-chemicals space, sharing HydRegen's model of engineering enzymes to displace traditional chemical catalysts and license the resulting processes.
  • AM Technology: UK-based specialist in continuous flow hydrogenation and reactor technology for pharmaceutical and fine chemical manufacturing. Listed as an active HydRegen partner on the Innovate UK-funded paracetamol scale-up project, and a direct peer/adjacent technology provider in continuous flow hydrogenation that competes for the same slots in customer process lines.

Emerging players

  • Ingenza: Scotland-based industrial biotechnology and synthetic biology company providing contract biocatalysis and fermentation services to pharma, chemicals, and consumer products companies. Emerging player in UK biocatalysis with overlapping customers and a similar use of engineering biology for sustainable chemical manufacturing, though focused on service/contract rather than licensing.

Broad incumbents

  • Johnson Matthey: Global specialty chemicals and sustainable technologies company with a major precious-metal catalysts business serving pharmaceutical and chemical manufacturers. Broad incumbent that HydRegen's biocatalytic hydrogenation directly competes with, especially in nitro-to-amine and other hydrogenation reactions where palladium and platinum catalysts are standard.
  • Evonik Industries: Major German specialty chemicals company with a sizable biocatalysis and enzyme production operation (formerly Evonik Creavis) addressing pharma, cosmetics, and fine chemicals. Broad incumbent that combines established commercial reach with internal biocatalysis R&D, creating a credible competitor and potential partner/customer for HydRegen's hydrogenation technology.
  • Novozymes (Novonesis): World-leading industrial enzyme company (recently merged with Chr. Hansen to form Novonesis) serving detergent, food, agriculture, and increasingly pharma/biocatalysis markets. Broad incumbent with deep enzyme engineering capability, established global sales channels, and capital scale that dwarf HydRegen, making it a potential competitor and partner in pharmaceutical biocatalysis.
  • BASF: World's largest chemical company with broad catalyst, biocatalysis, and process chemistry capabilities serving pharma, agro, and specialty chemical customers. Broad incumbent whose scale, in-house biocatalysis programs (e.g., with universities), and pricing power could constrain HydRegen's commercial expansion into large accounts.

Others

  • Almac Sciences: Pharmaceutical and fine chemicals CDMO that is both a HydRegen customer/partner (joint development, completed tech transfer of H2BioCat) and a service provider to many of HydRegen's target customers. Acts as an adjacent channel and ecosystem participant whose process development and scale-up infrastructure HydRegen leverages to reach pharma manufacturers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

HydRegen social profiles

Digital presence

HydRegen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HydRegen leadership team

Management profile

Number of profiles

Profiles8 records

HydRegen funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HydRegen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HydRegen

What does HydRegen do?

HydRegen develops and commercializes proprietary biocatalytic hydrogenation technology that replaces toxic, finite precious metal catalysts in chemical manufacturing with bio-based enzyme alternatives. The company's two core offerings are Bio2Amine, a heterogeneous biocatalyst for selective aromatic nitro-to-amine conversions, and H2BioCat, a hydrogenase-based technology platform providing 100% atom-efficient cofactor recycling for hydrogen-driven biocatalysis.

Is HydRegen a public or private company?

HydRegen is a private company. It is classified as venture growth investor backed and is currently operating.

When was HydRegen founded?

HydRegen was founded in 2021. It employs 11 to 50 people.

Where is HydRegen based?

HydRegen is headquartered in Oxford, United Kingdom, in the Europe region.

How does HydRegen make money?

Four revenue lines are on record. Technology Licensing is the primary driver. The others are joint Development Projects, evaluation Products and option to License Agreements.

Who are HydRegen's main competitors?

Direct peers on record are Oxford Biotrans, Codexis, Arzeda and AM Technology. Ingenza is listed as an emerging player. Broad incumbents are Johnson Matthey, Evonik Industries, Novozymes (Novonesis) and BASF. Almac Sciences is listed as an others.

Does HydRegen have an API?

No public API is recorded for HydRegen.

What industry is HydRegen in?

HydRegen's product category is Industrial Biotechnology. Its primary akta.pro industry code is IMAEAIAD, Chemical Synthesis Catalysts (Hydrogenation/Oxidation/Acid-Base), with a secondary code of EUABAJAC, Hydrogen & Derivative Fuels for Industry (H₂, Ammonia, Methanol). Its NAICS code is 325 and its SIC code is 2860.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0HydRegen Raises $8 Million Series A To Bring Biocatalysis To Industrial Chemical ManufacturingHydRegen raised $8 million in a Series A led by Genoa Ventures to expand its biocatalysis platform for industrial chemical manufacturing. The company's enzyme-based catalysts aim to replace precious-metal catalysts, making processes up to 40% more cost-effective and reducing emissions. Funding will support expansion into higher-volume markets and additional applications.citybizHydRegen Raises $8M Series A Led by Genoa Ventures to Expand Industrial Biocatalysis TechnologyHydRegen raised $8 million in a Series A led by Genoa Ventures to expand its biocatalysis technology. The funding will support adoption in agrochemicals, materials, and bulk chemical production, with claims of up to 40% cost reduction and lower emissions. The company plans to use the capital to expand customer adoption and develop additional industrial applications.FinancialContent Business PageHydRegen Raises $8M (£6M) Series A to Bring Biocatalysis to Industrial Chemical ManufacturingHydRegen closed $8 million in Series A funding led by Genoa Ventures. The biocatalytic platform replaces precious-metal catalysts in chemical manufacturing, aiming for up to 40% cost savings and lower emissions. The funds will expand adoption across chemicals, agrochemicals, and materials.Startup ResearcherHydRegen Raises $8 Million in Series A First CloseHydRegen raised $8 million in its Series A first close, led by Genoa Ventures. The biotech's enzyme-based catalysts replace precious-metal catalysts, potentially cutting costs by up to 40% and emissions. The funding will support expansion across chemical, agrochemical, and materials sectors.Scientist LiveNew funding competition to help bio-based innovations reach marketThe Industrial Biotechnology Innovation Centre (IBioIC) has launched the BioProcess Scale-up Accelerator Competition, offering up to £10,000 to support companies and academic teams in scaling bio-based innovations using its FlexBIO facility at Heriot-Watt University. Supported by the Scottish Government, the initiative aims to reduce commercialization risks by providing access to a 300-litre fermenter and technical expertise, building on successful pilot projects with entities like HydRegen. Applications are open until September 2026 for projects that can demonstrate viable manufacturing processes and contribute to Scotland's industrial biotechnology sector.HydregenoxfordInvesting in Green Chemistry: Why BioTech is a Big Opportunity — HydRegenHydRegen is promoting its bio-based technology as a solution for the chemical industry's transition to green chemistry, claiming significant reductions in CO2e emissions and operational costs. The article highlights the broader market opportunity, noting that global investment in green technology reached $755 billion in 2021 and forecasts a 10% compound annual growth rate for green chemicals over the next decade.HydregenoxfordHYDREGEN RAISE £2.6M — HydRegenOxford-based biotechnology company HydRegen has secured a £2.6 million investment in its latest funding round, led by the Clean Growth Fund. The capital will support the commercial development and deployment of HydRegen's bio-based catalysts over the next 18 months, aiming to decarbonize global chemical and pharmaceutical manufacturing processes.FinSMEsHydRegen Raises £2.6M in FundingHydRegen, an Oxford-based biotechnology company, raised £2.6M in funding led by the Clean Growth Fund. The company plans to use the capital for the commercial development and deployment of its sustainable chemical manufacturing technologies over the next 18 months. Additionally, HydRegen intends to expand its team within the next 12 months.BufferHydRegen raises £2.6 million to clean up the chemical manufacturing and pharmaceutical industriesOxford-based biotechnology company HydRegen has secured a £2.6 million investment led by Clean Growth Fund to advance its bio-based manufacturing technologies for the chemical and pharmaceutical sectors. The funding will support the commercial development of processes that replace toxic metal catalysts, potentially saving hundreds of thousands of tonnes of CO₂e annually in target applications like Paracetamol production.